Increased cytotoxicity and stability of Lipiodol-pirarubicin emulsion compared to classical doxorubicin-Lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinoma
Authors:
- Jean Pierre CercueilJCJean Pierre Cercueil
- Philippe FaurePFPhilippe Faure
- Liliana OsmakLOLiliana Osmak
- Nicolas IsambertNINicolas Isambert
- Jean Luc BeltramoJBJean Luc Beltramo
- François CognetFCFrançois Cognet
- Denis KrauseDKDenis Krause
- Laurent BedenneLBLaurent Bedenne
- Bruno ChauffertBCBruno Chauffert
- 1 November 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 12 (10) , 801-806
Abstract
There is no well-defined curative treatment for advanced and unresectable hepatocellular carcinoma. The widely used transarterial chemoembolization (TACE) with a doxorubicin-Lipiodol emulsion has not been shown to improve survival in randomized studies. Further, obstruction of the hepatic artery used in the procedure is badly tolerated in patients with cirrhosis. Drugs with a more rapid penetration into the cancer cells are likely to eliminate the need for obstruction of the hepatic artery. We therefore compared the cytotoxicity of another anthracycline pirarubicin with that of the commonly used doxorubicin. In this report, we show that pirarubicin has a greater in vitro cytotoxic effect than doxorubicin on the HepG2 and Hu-H7 human hepatoma cell lines. Pirarubicin emulsion with Lipiodol is more stable at 37°C than doxorubicin-Lipiodol. Moreover, pirarubicin accumulates at a greater extent in the oil phase, permitting Lipiodol to act as a slow-releasing vector for the anthracycline. Further, amiodarone, a multidrug resistance inhibitor, was shown to decrease the intrinsic resistance of HepG2 and Hu-H7 cells to both anthracyclines, and the presence of polysorbate 80 in the amiodarone preparation increased the stability of the anthracycline-Lipiodol emulsions. We therefore conclude that pirarubicin is a better candidate for TACE than doxorubicin. The rapid and increased cytotoxicity of pirarubicin on hepatoma cancer cells and the stability of the pirarubicin-Lipiodol amiodarone emulsion could avoid the complete obstruction of the hepatic artery by Gelfoam sponges, and provide a better tolerated method of TACE in patients with latent liver insufficiency.Keywords
This publication has 20 references indexed in Scilit:
- Evaluation of the Therapeutic Effect of Transcatheter Arterial Embolization for Hepatocellular CarcinomaOncology, 2000
- Treatment of Hepatocellular CarcinomaDigestion, 1998
- Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trialJournal of Hepatology, 1998
- Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institutionHepatology, 1998
- Ethiodized oil emulsions in hepatic microcirculation: In vivo microscopy in animal modelsAcademic Radiology, 1997
- A Comparison of Lipiodol Chemoembolization and Conservative Treatment for Unresectable Hepatocellular CarcinomaNew England Journal of Medicine, 1995
- Treatment of hepatocellular carcinoma with transcatheter arterial embolization. Analysis of prognostic factorsCancer, 1994
- Benign and malignant nodules in cirrhotic livers: distinction based on blood supply.Radiology, 1991
- A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinomaJournal of Hepatology, 1990
- A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin spongeCancer, 1987